Evidence map›Paper›PMID 24611008›Full record

ArticleInternational journal of nanomedicine2014

Self-microemulsifying drug-delivery system for improved oral bioavailability of 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol: preparation and evaluation.

Shuang Cai, Cai-Hong Shi, Xiangrong Zhang, Xiaojiao Tang, Hao Suo, Li Yang, Yuqing Zhao

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Anticancer 20(R)-dammarane-3β,12β,20,25-tetrol-loaded polymeric micelles: Preparation, quantification and pharmacokinetics.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2016
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shuang CaiDepartment of Pharmacy, The First Affiliated Hospital of China Medical University, People's Republic of China.
Cai-Hong ShiShenyang Pharmaceutical University, Shenyang, People's Republic of China.
Xiangrong ZhangShenyang Pharmaceutical University, Shenyang, People's Republic of China.
Xiaojiao TangShenyang Pharmaceutical University, Shenyang, People's Republic of China.
Hao SuoShenyang Pharmaceutical University, Shenyang, People's Republic of China.
Li YangShenyang Pharmaceutical University, Shenyang, People's Republic of China.
Yuqing ZhaoShenyang Pharmaceutical University, Shenyang, People's Republic of China.
Shenyang Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to develop a self-microemulsifying drug delivery system (SMEDDS) to enhance the oral bioavailability of the poorly water-soluble compound 20(S)-25-methoxydammarane-3β;12β;20-triol (25-OCH3-PPD). Optimized SMEDDS formulations for 25-OCH3-PPD contained Cremophor® EL (50%) as the surfactant, glycerin (20%) as the cosurfactant, and Labrafil® M1944 (30%) as the oil. The SMEDDS were characterized by morphological observation and mean droplet size. The pharmacokinetics and bioavailability of the 25-OCH3-PPD suspension and SMEDDS were evaluated and compared in rats. The plasma concentrations of 25-OCH3-PPD and its main metabolite, 25-OH-PPD, were determined by ultra performance liquid chromatography-tandem mass spectrometry. The relative bioavailability of SMEDDS was dramatically enhanced by an average of 9.8-fold compared with the suspension. Improved solubility and lymphatic transport may contribute to this enhanced bioavailability. Our studies highlight the promise of SMEDDS for the delivery of 25-OCH3-PPD via the oral route.

Indexed as

Drug Delivery SystemsAdministration, OralAnimalsBiological AvailabilityChemistry, PharmaceuticalDrug StabilityEmulsionsFemaleGinsenosidesMaleNanomedicineRatsRats, WistarSapogeninsSolubilitySurface-Active Agents25-hydroxyprotopanaxadiolEmulsionsGinsenosidesSapogeninsSurface-Active Agents12β20-triol (25-OCH3-PPD)25-methoxydammarane-3β25-OH-PPDbioavailabilitypharmacokineticsself-microemulsifying drug delivery system

Identifiers

PMID24611008
PMCPMC3928458
OpenAlexW2043810138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.